{"uid":"cap_XwIallc_jJHB2zHsJ9Z0A","slug":"magent-hfa-icos-her2-baseline-cardiovascular-risk-calculator-978b626d","name":"magent HFA-ICOS HER2 Baseline Cardiovascular Risk Calculator","description":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential anthracycline before HER2 is Medium 1. Deterministic published classification with citation; not a treatment order. magent does not measure LVEF or biomarkers.","url":"https://api.magentlab.com/api/calc/hfa_icos_her2","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","required":["age_years","lvef_percent","heart_failure_or_cardiomyopathy","prior_trastuzumab_cardiotoxicity","mi_or_cabg","stable_angina","severe_valvular_heart_disease","concurrent_anthracycline_and_her2","arrhythmia","elevated_troponin","elevated_bnp","prior_remote_anthracycline","prior_left_chest_or_mediastinal_rt","hypertension","diabetes","ckd","anthracycline_before_her2","current_or_significant_smoker","obesity"],"properties":{"ckd":{"type":"boolean","description":"Chronic kidney disease as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."},"obesity":{"type":"boolean","description":"Obesity as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false. magent does not compute BMI."},"diabetes":{"type":"boolean","description":"Diabetes mellitus as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."},"age_years":{"type":"integer","description":"Age in years (integer 18-100). Lyon 2020 exclusive bands: ≥80 is High; 65-79 is Medium 2 (2 points); younger than 65 does not score. Age 80 is High, not Medium 2."},"arrhythmia":{"type":"boolean","description":"Atrial fibrillation, atrial flutter, VT, or VF as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not interpret the ECG."},"mi_or_cabg":{"type":"boolean","description":"Prior myocardial infarction or CABG as assigned by the caller (Lyon 2020 HER2 table High). true or false."},"elevated_bnp":{"type":"boolean","description":"Elevated BNP or NT-proBNP as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay natriuretic peptides."},"hypertension":{"type":"boolean","description":"Hypertension as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."},"lvef_percent":{"type":"integer","description":"Left-ventricular ejection fraction percent (integer 10-80) as assigned by the caller. <50 is High; 50-54 is Medium 2 (2 points); ≥55 does not score. magent does not measure LVEF."},"stable_angina":{"type":"boolean","description":"Stable angina as assigned by the caller (Lyon 2020 HER2 table High). true or false."},"elevated_troponin":{"type":"boolean","description":"Elevated troponin as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay troponin."},"anthracycline_before_her2":{"type":"boolean","description":"Current regimen includes anthracycline before HER2-targeted therapy, sequential not concurrent (Lyon 2020 HER2 table Medium 1). true or false. Ignored for points when concurrent_anthracycline_and_her2 is true."},"prior_remote_anthracycline":{"type":"boolean","description":"Prior remote anthracycline for a previous malignancy, not the current protocol (Lyon 2020 HER2 table footnote g; Medium 2). true or false."},"current_or_significant_smoker":{"type":"boolean","description":"Current or significant smoking history as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."},"severe_valvular_heart_disease":{"type":"boolean","description":"Severe valvular heart disease as assigned by the caller (Lyon 2020 HER2 table High). true or false."},"heart_failure_or_cardiomyopathy":{"type":"boolean","description":"Heart failure or cardiomyopathy as assigned by the caller (Lyon 2020 HER2 table Very high). true or false."},"prior_trastuzumab_cardiotoxicity":{"type":"boolean","description":"Prior trastuzumab cardiotoxicity as assigned by the caller (Lyon 2020 HER2 table Very high). true or false. magent does not review prior exposure."},"concurrent_anthracycline_and_her2":{"type":"boolean","description":"Anthracycline and trastuzumab delivered concurrently on the current protocol (Lyon 2020 HER2 table footnote f; High). true or false. When true, anthracycline_before_her2 does not add Medium 1 points."},"prior_left_chest_or_mediastinal_rt":{"type":"boolean","description":"Prior left-chest or mediastinal radiotherapy as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false."}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_HDqIXF5x1n76FNLA2GgzA","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.005","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Classifies baseline cardiovascular risk (Very High / High / Medium 1 / Medium 2 / Low) before HER2-targeted therapy (trastuzumab and related agents) per the Lyon 2020 HFA-ICOS published criteria.","exampleAgentPrompt":"Classify the baseline cardiovascular risk before starting trastuzumab for a 72-year-old patient with LVEF 58%, no heart failure, no prior trastuzumab cardiotoxicity, no MI or CABG, no stable angina, no severe valvular disease, no concurrent anthracycline, no arrhythmia, no elevated troponin or BNP, no prior remote anthracycline, no prior chest radiation, hypertension present, no diabetes, no CKD, no prior sequential anthracycline, non-smoker, and not obese — use the Lyon 2020 HFA-ICOS criteria and tell me the risk category and expected cardiotoxicity rate.","exampleUseCases":[{"title":"Pre-treatment trastuzumab risk stratification","prompt":"My patient is 68 years old with LVEF 55%, has hypertension and diabetes, is not obese, no CKD, no arrhythmia, no elevated troponin or BNP, no history of heart failure, MI, CABG, stable angina, or valvular disease, no prior trastuzumab cardiotoxicity, no concurrent or sequential anthracycline, no prior chest radiation, and is a non-smoker. What is her baseline cardiovascular risk category before starting trastuzumab under the Lyon 2020 HFA-ICOS framework?"},{"title":"High-risk flagging with concurrent anthracycline","prompt":"A 55-year-old breast cancer patient is about to receive concurrent anthracycline and HER2-targeted therapy. LVEF is 60%, no heart failure or prior trastuzumab cardiotoxicity, no MI, CABG, angina, or valvular disease, no arrhythmia, normal troponin and BNP, no prior anthracycline or chest radiation, no hypertension, diabetes, CKD, smoking, or obesity. What does the HFA-ICOS HER2 classification say about her baseline cardiac risk and estimated cardiotoxicity incidence?"},{"title":"Sequential anthracycline prior to HER2 therapy","prompt":"Patient is 61 years old, LVEF 62%, received anthracycline chemotherapy sequentially before HER2 therapy, no concurrent anthracycline now, no heart failure, no prior trastuzumab toxicity, no MI or CABG, no angina or valvular disease, no arrhythmia, troponin and BNP normal, no prior chest radiation, has hypertension but no diabetes, no CKD, non-smoker, not obese. Using the Lyon 2020 HFA-ICOS criteria, classify this patient's baseline cardiovascular risk before HER2-targeted therapy."}],"resultDescription":"Returns a deterministic cardiovascular risk category (Very High, High, Medium 1, Medium 2, or Low) per Lyon 2020 HFA-ICOS published classification, an estimated cardiotoxicity incidence band (<2%, 2-9%, 10-19%, or >=20%), the specific factors driving the classification, and the published citation. Does not measure LVEF or biomarkers directly — these are caller-supplied.","failureModes":["Missing required query parameters (age_years, lvef_percent, or any boolean flag) returns a validation error","Age outside the 18-100 integer range may return an error or unexpected classification","Caller misassigns clinical variables (e.g. arrhythmia, troponin elevation) — garbage-in garbage-out; endpoint trusts caller-supplied booleans","Payment failure (x402) returns 402 status with payment instructions rather than a risk classification","Conflicting flag combinations (e.g. both concurrent and sequential anthracycline) may produce unexpected tier assignments"],"whenToPreferThis":"Use this endpoint when you need a deterministic, citation-backed cardiovascular risk classification per the Lyon 2020 HFA-ICOS framework specifically for HER2-targeted therapy (trastuzumab and related agents). Prefer it over generic risk calculators when the clinical context is pre-HER2 therapy cardiotoxicity risk stratification, especially when the treating team has already assessed clinical variables and needs a structured tier (Very High / High / Medium 1 / Medium 2 / Low) with an associated cardiotoxicity incidence estimate and literature citation. Not appropriate for LVEF measurement, biomarker assay, treatment ordering, or non-HER2 chemotherapy risk stratification.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T13:05:05.388Z","isFirstParty":false}